Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age65+
SponsorRuijin Hospital
About this trial
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Eligibility criteria
Qualifiers
Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;
Double or triple hit confirmed by pathology;
Age ≥ 65 years old;
ECOG performance status score of 0, 1, or 2;
Disqualifiers
There is a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;
Primary central nervous system lymphoma;
Left ventricular ejection fraction (LVEF) is less than or equal to 50%;
Trial design
Treatments tested in this trial
- CL-Pola-R-CHP
Treatment groups
28 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov